GlassScriptPhysician profile
Jamica Taylor
NPI 1356122386
$2,690.17
in general payments reported to CMS, 2019-2025
13 companies · $788 in 2025
The $788 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.11 · 2024: $1,882 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $724.18 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $371.63 | 2024-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $370.32 | 2024-2025 | Invega Sustenna, Invega Trinza |
| E.R. Squibb & Sons, L.L.C. | $278.11 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $242.40 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $209.86 | 2024-2025 | Abilify Asimtufii |
| Axsome Therapeutics, INC. | $122.48 | 2024 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $97.60 | 2024-2025 | Abilify Asimtufii |
| Indivior INC. | $96.03 | 2024-2025 | Sublocade, Perseris |
| Abbvie INC. | $69.98 | 2024-2025 | |
| Braeburn INC. | $47.48 | 2024-2025 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $41.11 | 2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.99 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamica Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.